InvestorsHub Logo
Followers 11
Posts 330
Boards Moderated 0
Alias Born 08/18/2012

Re: Ned Serious post# 2319

Wednesday, 03/19/2014 10:50:11 PM

Wednesday, March 19, 2014 10:50:11 PM

Post# of 6939
Cellceutix Corp CTIX is a company a friend had told me about in Oct 2012 which I bought a few thousand shares at .56 off the rip. At that time I was very new to trading with very little experience, after doing tons of DD on this company and reading different boards and peoples opinion I really began to believe in this company. I never sold any and have been buying all the way up to as high as 1.90.

CTIX has 3 drugs in there pipeline one being Kevetrin which if all goes as planned this will be a blockbuster. Kevetrin is currently undergoing clinical trials at Harvard Cancer Center, Dana Farber and Beth Iserael. The Dana Farber trail for solid rumors just reached cohort 7 dosing at 165mg and through 6 cohorts the MTD has yet to be reached. This should end in April or May I believe and results should be in by Nov with no delays.

They also just starting enrolling patients for the Phase 2b trail for Brilacidin which targets Acute Bacterial Skin and Skin Stricture Infections. Brilacidin was acquired from Polymedix in Sept 2013 CTIX management believes this has a 100 million dollar market potential. This trail is also scheduled to be completed by Nov!

http://clinicaltrials.gov/ct2/show/NCT01664000?term=Cellceutix+Pharmaceuticals&rank=2

http://clinicaltrials.gov/ct2/show/NCT02052388?term=Cellceutix+Pharmaceuticals&rank=1

CTIX recently submitted an IND for there Anti Psoriasis drug Prurisol on Feb 18 which the FDA has 30 days to answer so we should be getting news on that any day now!

I'm in this long CTIX has a great pipeline in my opinion and I have faith that Kevetrin will be a blockbuster in the future! I'd love to get some opinions from more experienced traders on this company!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.